Loading...
IVCR.Q logo

Invacare CorporationOTCPK:IVCR.Q Rapporto sulle azioni

Cap. di mercato US$512.8k
Prezzo delle azioni
n/a
Il mio valore equo
Non disponibile
1Y-99.1%
7D-10.6%
1D
Valore del portafoglio
​
Vista

Invacare Corporation

Report azionario OTCPK:IVCR.Q

Capitalizzazione di mercato: US$512.8k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Invacare (IVCR.Q) Panoramica del titolo

Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. Maggiori dettagli

IVCR.Q analisi fondamentale
Punteggio fiocco di neve
Valutazione2/6
Crescita futura0/6
Prestazioni passate0/6
Salute finanziaria1/6
Dividendi0/6

Analisi del rischio

Gli utili sono diminuiti del 2.6% all'anno negli ultimi 5 anni

Non ha una capitalizzazione di mercato significativa ( $513K )

Prezzo delle azioni altamente volatile negli ultimi 3 mesi rispetto al mercato US

Ha meno di 1 anno di pista di cassa

+ 1 più rischio

IVCR.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di Invacare Corporation

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Invacare
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$0.013
Massimo di 52 settimaneUS$1.64
Minimo di 52 settimaneUS$0.011
Beta0.51
Variazione di 1 mese-10.00%
Variazione a 3 mesi-62.60%
Variazione di 1 anno-99.09%
Variazione a 3 anni-99.77%
Variazione a 5 anni-99.92%
Variazione dall'IPO-99.49%

Notizie e aggiornamenti recenti

Recent updates

Seeking Alpha • Feb 01

Invacare falls on bankruptcy filing

Medical equipment maker Invacare Corporation (NYSE:IVC) lost ~20% in the pre-market trading Wednesday after announcing that the company and two U.S.-based subsidiaries filed for voluntary Chapter 11 bankruptcy. The cases, filed in the Bankruptcy Court for the Southern District of Texas, do not include its international operations and are not expected to impact the company’s ability to serve its global clientele, Invacare (IVC) said. The bankruptcy cases follow a financial restructuring agreement the company inked with almost all of its debt holders and most of the convertible noteholders. The deal, known as Restructuring Support Agreement, allows Invacare (IVC) to reduce its debt by ~$240M and provides the company with $60M equity capital to repay certain debt and fund its transformation plan. “The company expects to emerge with significantly less debt on its balance sheet and will secure additional liquidity to support long-term growth,” Invacare’s (IVC) recently appointed Chief Executive Geoff Purtill noted.
Seeking Alpha • Dec 27

Invacare announces additional draw of $5.5M term loans

Invacare (NYSE:IVC) announced additional draw of $5.5M of term loans under its credit agreement. The company said certain funds will be managed by Highbridge Capital Managed. The company will use the proceeds of the additional draw for general corporate purposes, it said. About $14M of additional liquidity remains available under the Amended Highbridge Credit Agreement, subject to satisfaction of certain conditions set forth therein.
Articolo di analisi • Nov 14

Invacare Corporation (NYSE:IVC) Analysts Just Slashed Next Year's Estimates

Market forces rained on the parade of Invacare Corporation ( NYSE:IVC ) shareholders today, when the analysts...
Seeking Alpha • Nov 07

Invacare GAAP EPS of -$0.92, revenue of $170.4M

Invacare press release (NYSE:IVC): Q3 GAAP EPS of -$0.92. Revenue of $170.4M (-24.0% Y/Y). Gross margin was 18.4%, a decrease of 850 basis points, including 510 basis points of decline related to the write-down of respiratory inventory as a result of the decision to discontinue production of respiratory products. SG&A expense decreased 1.4% to $55.4 million, and constant currency SG&A increased 4.5%. Operating loss was $33.4 million compared to a loss of $24.8 million. Adjusted EBITDA loss was $11.8 million, compared to positive $8.0 million. Free cash flow usage was $20.5 million compared to usage of $6.1 million.
Seeking Alpha • Sep 29

Invacare receives non-compliance letter from NYSE

Invacare (NYSE:IVC) said on Thursday it had received notice from the New York Stock Exchange that it was not in compliance with the NYSE listed company manual as the average closing price was less than $1 per share over a consecutive 30 trading-day period. The company plans to notify the NYSE by October 7 on its plan to return to compliance with the NYSE continued listing standard. The company can regain compliance at any time within the six-month period. The company is required to have a closing share price of at least $1 over a consecutive 30 trading-day period. The company intends to consider available alternatives, including, but not limited to, a reverse stock split, subject to shareholder approval no later than at the company’s next annual meeting of shareholders.
Seeking Alpha • Aug 29

Invacare names Geoffrey Purtill as interim president and executive chief

Invacare (NYSE:IVC) on Monday has named Geoffrey P. Purtill as the company's interim president and chief executive officer, succeeding departing chairman, president and CEO Matthew E. Monaghan. The transition is effective Aug. 28, 2022. Geoffrey P. Purtill had been serving as the Invacare's senior vice president and general manager, EMEA and APAC.  "We welcome Geoff who has distinguished himself throughout his tenure with Invacare. The Board has full confidence that he has the right skillset and industry experience to lead the company through this transition as we search for a permanent successor who can accelerate the achievement of our objectives," said Cliff Nastas, Invacare’s lead independent director. In addition, the Board has announced the appointment of Michael J. Merriman as its director and non-executive Chairman. Merriman previously served as chair of the company's audit committee from 2014 to 2018. "As the independent Chairman of the Board, Merriman succeeds Cliff Nastas as the company's lead independent director," report.  IVC stock jumps 9% in premarket on Monday to trade at $0.94 vs 52-week level of $0.80 to $8.73.
Seeking Alpha • Aug 23

Invacare adds two new directors after deal with largest investor Azurite

Medical equipment maker Invacare Corporation (NYSE:IVC) has appointed two new directors with immediate effect as part of a corporation agreement with its largest shareholder, Azurite Management LLC, which owns more than 10% of IVC stock. The new directors, Steven H. Rosen and Edward F. Crawford will replace Julie A. Beck and Stephanie L. Fehr, who resigned from the board on Aug. 22. Mr. Rosen is the Co-Founder, and Co-Chief Executive of Ohio-based private equity firm Resilience Capital Partners LLC. Crawford, a former U.S. ambassador to Ireland from 2019 to 2021, currently serves Resilience as a Member of its Board of Advisors. As part of the deal, IVC has agreed to set up a five-member Strategy and Operational Improvement Committee comprising the new appointees. The terms of the corporation agreement include certain standstill provisions which, among other things, will bar Azurite from raising its IVC stake above 19.9%.
Articolo di analisi • Apr 30

Returns Are Gaining Momentum At Invacare (NYSE:IVC)

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Articolo di analisi • Jan 27

Invacare (NYSE:IVC) Use Of Debt Could Be Considered Risky

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Articolo di analisi • Dec 01

Returns On Capital Are Showing Encouraging Signs At Invacare (NYSE:IVC)

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Articolo di analisi • Sep 30

Here's Why Invacare (NYSE:IVC) Is Weighed Down By Its Debt Load

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Articolo di analisi • Aug 06

When Should You Buy Invacare Corporation (NYSE:IVC)?

Invacare Corporation ( NYSE:IVC ), might not be a large cap stock, but it saw a decent share price growth in the teens...
Articolo di analisi • May 14

Increases to CEO Compensation Might Be Put On Hold For Now at Invacare Corporation (NYSE:IVC)

In the past three years, the share price of Invacare Corporation ( NYSE:IVC ) has struggled to grow and now...
Articolo di analisi • May 03

Returns On Capital Are Showing Encouraging Signs At Invacare (NYSE:IVC)

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Articolo di analisi • Mar 03

Invacare Corporation's (NYSE:IVC) Path To Profitability

We feel now is a pretty good time to analyse Invacare Corporation's ( NYSE:IVC ) business as it appears the company may...
Articolo di analisi • Feb 05

Invacare (NYSE:IVC) Has A Somewhat Strained Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Articolo di analisi • Jan 10

What Can The Trends At Invacare (NYSE:IVC) Tell Us About Their Returns?

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Articolo di analisi • Dec 14

Invacare's(NYSE:IVC) Share Price Is Down 48% Over The Past Five Years.

It is a pleasure to report that the Invacare Corporation ( NYSE:IVC ) is up 33% in the last quarter. But over the last...
Articolo di analisi • Nov 23

Invacare Corporation's (NYSE:IVC) Shift From Loss To Profit

With the business potentially at an important milestone, we thought we'd take a closer look at Invacare Corporation's...

Rendimenti per gli azionisti

IVCR.QUS Medical EquipmentUS Mercato
7D-10.6%-0.5%0.8%
1Y-99.1%-20.2%24.2%

Ritorno vs Industria: IVCR.Q ha avuto una performance inferiore rispetto al US Medical Equipment che ha registrato un rendimento -20.2 % nell'ultimo anno.

Rendimento vs Mercato: IVCR.Q ha avuto una performance inferiore al mercato US che ha registrato un rendimento 24.2 % nell'ultimo anno.

Volatilità dei prezzi

Is IVCR.Q's price volatile compared to industry and market?
IVCR.Q volatility
IVCR.Q Average Weekly Movement28.2%
Medical Equipment Industry Average Movement8.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di IVCR.Q è stato volatile rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale ( 28% ) di IVCR.Q è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
18852,800Geoff Purtillwww.invacare.com

Invacare Corporation Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Invacare con la sua capitalizzazione di mercato?
IVCR.Q statistiche fondamentali
Capitalizzazione di mercatoUS$512.81k
Utili (TTM)-US$101.07m
Ricavi(TTM)US$741.73m
0.0x
Rapporto P/S
0.0x
Rapporto P/E

IVCR.Q è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
IVCR.Q Conto economico (TTM)
RicaviUS$741.73m
Costo del fatturatoUS$557.69m
Profitto lordoUS$184.04m
Altre speseUS$285.12m
Utili-US$101.07m

Ultimi utili riportati

Dec 31, 2022

Prossima data di guadagno

n/a

Utile per azione (EPS)-2.66
Margine lordo24.81%
Margine di profitto netto-13.63%
Rapporto debito/patrimonio netto436.8%

Come si è comportato IVCR.Q nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2023/05/05 22:48
Prezzo dell'azione a fine giornata2023/05/05 00:00
Utili2022/12/31
Utili annuali2022/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Invacare Corporation è coperta da 7 analisti. di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Robert LabickCJS Securities, Inc.
Constantine DavidesD. Boral Capital LLC.
Matthew MishanKeyBanc Capital Markets Inc.